FDA Misses Deadline on Savara’s Inhaled Drug for Rare Lung Disease
The FDA will not meet the Nov. 22, 2026 deadline for Savara’s molgramostim BLA for autoimmune PAP. The review is ongoing with no new date set.
Already have an account? Sign in.